Dopavision
$13Mlatest round · Venture round · Jul 2021 · 5 yr ago
$3.1Mgrants · 3 grants · CORDIS
16stories in the press
2017founded
Overview
At Dopavision, we believe everyone deserves to see the world clearly through healthy eyes. Learn about our mission to develop an innovative and widely accessible myopia intervention today.
Funding and backers
Total raised
$13M
4 rounds on record
Latest round
$13M
Venture round · Jul 2021 · 5 yr ago
Grants
$3.1M
3 grants · CORDIS
The money's age
Long since its last round
63 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Mar 21, 2023
New executive Dopavision Appoints Prof. Dr. Jens Ellrich as Chief Scientific Officer · dopavision.com
Jun 1, 2022
Won a grant $1.4M · CORDIS
Jun 1, 2022
Won a grant $119k · CORDIS
May 24, 2022
New executive Dopavision Appoints Mark S. Wuttke, Ph.D., as Chief Executive Officer · streetinsider.com
Jul 18, 2021
Raised a round Venture round $13M · pharmaphorum
Jun 1, 2018
Won a grant $1.6M · CORDIS
2017
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | Jun 2022 | $119k | — | CORDIS |
| Grant | Jun 2022 | $1.4M | — | CORDIS |
| Venture round | Jul 2021 | $13M | — | pharmaphorum |
| Grant | Jun 2018 | $1.6M | — | CORDIS |
Registers and programsofficial lists and records that name the company
| Legal entity | Dopavision GmbH | its site |
| Registered | 7 Nov 2017 |
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Features Pricing About FAQ Contact About OneShelf Built for the shopper tired of guessing. We believe everyone deserves a knowledgeable…
Modern Health is a mental health and wellbeing platform that provides comprehensive care, support, and resources to individuals and…
Contact About Leadership About Making Quality Pharmacy Care Accessible to Every Community At OneroRx, caring for our communities is at the…
**We are hiring clinicians!** Daybreak is a purpose-driven company solving one of the most defining problems of our generation: youth…
Soilytix was founded by people with a deep passion for soil biology. We believe the life beneath our feet deserves to be seen, understood…
Puch AI Integrations About Contact Try now We are on a mission to make AI accessible to everyone We're building on a simple mission…
News
Dopavision Presented Key Data from its MyopiaX-1 Clinical Trial at the 19th International Myopia Conference
- First Data Presentation: Friday's presentation marked the first public disclosure of the 6-month data from the MyopiaX-1 clinical trial in children with myopia (NCT04967287). - MyopiaX Clinical Outcomes: MyopiaX demonstrated positive proof of concept at
Read more
Report
Dopavision Announces Topline Results in Clinical Trial of Targeted Photobiomodulation Approach for Progressive Myopia
- Safe and Tolerable: MyopiaX-1 proof-of-concept clinical trial (NCT04967287) supports MyopiaX's excellent safety and tolerability profile with no untoward safety events. - Novel Approach: Dopavision's approach to delivering targeted photobiomodulation to
Read more
Report
Dopavision Announces Topline Results in Clinical Trial of Targeted Photobiomodulation Approach for Progressive Myopia
Read more
Report
Dopavision Reports Successful Completion of Enrollment for MyopiaX-1 Trial
- MyopiaX-1 trial to generate first clinical evidence with MyopiaX, a novel therapeutic approach to manage myopia progression - First data readout expected in Q1/ 2024 with study completion planned for September 2024 Berlin, Germany, September 26, 2023 -
Read more
Report
Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Active
- First-in-human clinical trial of MyopiaX, the first therapeutic approach in juvenile myopia to target the dopamine pathway digitally- Enrollment ongoing in Germany, Spain, the Netherlands, and the United Kingdom Berlin, Germany, June 28, 2023 - Dopavisi
Read more
Report
Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Active
- First-in-human clinical trial of MyopiaX, the first therapeutic approach in juvenile myopia to target the dopamine pathway digitally- Enrollment ongoing in Germany, Spain, the Netherlands, and the United Kingdom Berlin, Germany, June 28, 2023 --- Dopavi
Read more
Report
Dopavision Appoints Prof. Dr. Jens Ellrich as Chief Scientific Officer
- Leading translational medicine and neuroscience expert to head Dopavision's research activities Berlin, Germany, March 21, 2023 - Dopavision, a clinical-stage company pioneering the development of digitally delivered light-based therapeutics, today anno
Read more
Report
Report
Dopavision Appoints Dr. Dirk Sauer as Chair of the Company's Advisory Board
- Former Head of Novartis' Ophthalmology Development Unit to provide significant product development expertise and industry network Berlin, Germany, November 16, 2022 - Dopavision, a clinical-stage company pioneering the development of digital therapeutic
Read more
Report
Printable Resources
PRINTABLE RESOURCES Return to Portal Home Downloadable Resource Welcome letter Storyboard EN DOCPPT DE DOCPPT ES DOCPDF PT DOCPDF NL DOCPDF Daily schedule Activity cards Weekly schedule (1) Weekly schedule (2) Monthly schedule PDFPDFPDFPDFPDF PDFPDFPDFPDF
Read more
Report
Show more news